2021
A glycoside analog of mammalian oligomannose formulated with a TLR4-stimulating adjuvant elicits HIV-1 cross-reactive antibodies. Bruxelle JF, Kirilenko T, Trattnig N, Yang Y, Cattin M, Kosma P, Pantophlet R. Sci Rep. 2021 Feb 25;11(1):4637.
HIV-1 entry and prospects for protecting against infection. Bruxelle JF, Trattnig N, Mureithi MW, Landais E, Pantophlet R. Microorganisms. 2021 Jan 22;9(2):228. doi: 10.3390/microorganisms9020228.
2020
Serum alpha-mannosidase as an additional barrier to eliciting oligomannose-specific HIV-1-neutralizing antibodies. Bruxelle JF, Kirilenko T, Qureshi Q, Lu N, Trattnig N, Kosma P, Pantophlet R. Sci Rep. 2020 May 5;10(1):7582. doi: 10.1038/s41598-020-64500-8.
2019
Synthesis of an undecasaccharide featuring an oligomannosidic heptasaccharide and a bacterial Kdo-lipid A backbone for eliciting neutralizing antibodies to mammalian oligomannose on the HIV-1 envelope spike. Trattnig N, Blaukopf M, Bruxelle JF, Pantophlet R, Kosma P. J Am Chem Soc. 2019 May 15;141(19):7946-7954. doi: 10.1021/jacs.9b02872. Epub 2019 Apr 30.
Comparative antigenicity of thiourea- and adipic amide linked neoglycoconjugates containing modified oligomannose epitopes for the carbohydrate-specific anti-HIV antibody 2G12. Trattnig N, Mayrhofer P, Kunert R, Mach L, Pantophlet R, Kosma P. Bioconjug Chem. 2019 Jan 16;30(1):70-82. doi: 10.1021/acs.bioconjchem.8b00731. Epub 2018 Dec 28.
2017
Synthesis of a Pentasaccharide Fragment Related to the Inner Core Region of Rhizobial and Agrobacterial Lipopolysaccharides. Trattnig N, Farcet JB, Gritsch P, Christler A, Pantophlet R, Kosma P. J Org Chem. 2017 Dec 1;82(23):12346-12358. doi: 10.1021/acs.joc.7b02172. Epub 2017 Oct 26.
Bacterially derived synthetic mimetics of mammalian oligomannose prime antibody responses that neutralize HIV infectivity. Pantophlet R, Trattnig N, Murrell S, Lu N, Chau D, Rempel C, Wilson IA, Kosma P. Nat Commun. 2017 Nov 17;8(1):1601. doi: 10.1038/s41467-017-01640-y.
2015
Identification of CD4-Binding Site Dependent Plasma Neutralizing Antibodies in an HIV-1 Infected Indian Individual. Khan L, Makhdoomi MA, Kumar S, Nair A, Andrabi R, Clark BE, Auyeung K, Bhattacharya J, Vajpayee M, Wig N, Pantophlet R, Luthra K. PLoS One. 2015 May 11;10(5):e0125575. doi: 10.1371/journal.pone.0125575. eCollection 2015.
Crystal structure of the HIV neutralizing antibody 2G12 in complex with a bacterial oligosaccharide analog of mammalian oligomannose. Stanfield RL, De Castro C, Marzaioli AM, Wilson IA, Pantophlet R. Glycobiology. 2015 Apr;25(4):412-9. doi: 10.1093/glycob/cwu123. Epub 2014 Nov 7.
2014
The presence of glutamine at position 315 but not epitope masking predominantly hinders HIV subtype C neutralization by the anti-V3 antibody B4e8. Manhas S, Chau D, Rempel C, Clark BE, Auyeung K, Pantophlet R. Virology. 2014 Aug;462-463:98-106. doi: 10.1016/j.virol.2014.05.034. Epub 2014 Jun 25.
2013
Pantophlet, R. (ed.). HIV Glycans in Infection and Immunity. New York: Springer, 2013.
2G12-expressing B cell lines may aid in HIV carbohydrate vaccine design strategies. Doores KJ, Huber M, Le KM, Wang SK, Doyle-Cooper C, Cooper A, Pantophlet R, Wong CH, Nemazee D, Burton DR. J Virol. 2013 Feb;87(4):2234-41. doi: 10.1128/JVI.02820-12. Epub 2012 Dec 5.
2012
A bacterial lipooligosaccharide that naturally mimics the epitope of the HIV-neutralizing antibody 2G12 as a template for vaccine design. Clark BE, Auyeung K, Fregolino E, Parrilli M, Lanzetta R, De Castro C, Pantophlet R. Chem Biol. 2012 Feb 24;19(2):254-63. doi: 10.1016/j.chembiol.2011.12.019.
Complex binding sites made to order. Scott JK, Pantophlet R, Craig L. Nat Biotechnol. 2012 Feb 8;30(2):154-5. doi: 10.1038/nbt.2118. No abstract available.
An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site. Ahmed FK, Clark BE, Burton DR, Pantophlet R. Vaccine. 2012 Jan 20;30(5):922-30. doi: 10.1016/j.vaccine.2011.11.089. Epub 2011 Dec 4.
2011
Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site. Alexandre KB, Gray ES, Pantophlet R, Moore PL, McMahon JB, Chakauya E, O’Keefe BR, Chikwamba R, Morris L. J Virol. 2011 Sep;85(17):9039-50. doi: 10.1128/JVI.02675-10. Epub 2011 Jun 22.
2010
Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds. Astronomo RD, Kaltgrad E, Udit AK, Wang SK, Doores KJ, Huang CY, Pantophlet R, Paulson JC, Wong CH, Finn MG, Burton DR. Chem Biol. 2010 Apr 23;17(4):357-70. doi: 10.1016/j.chembiol.2010.03.012.
Antibody epitope exposure and neutralization of HIV-1. Pantophlet R. Curr Pharm Des. 2010;16(33):3729-43. Review.
2009
Report on the AIDS Vaccine 2008 Conference. Alter G, Ananworanich J, Pantophlet R, Rybicki EP, Buonaguro L. Hum Vaccin. 2009 Mar;5(3):119-25. Epub 2009 Mar 8.
The human immunodeficiency virus type 1 envelope spike of primary viruses can suppress antibody access to variable regions. Pantophlet R, Wang M, Aguilar-Sino RO, Burton DR. J Virol. 2009 Feb;83(4):1649-59. doi: 10.1128/JVI.02046-08. Epub 2008 Nov 26.
2008
Pantophlet, R. (2008). Lipopolysaccharides of Acinetobacter. In U. Gerischer (Ed.), Acinetobacter Molecular Biology. Horizon Scientific Press (pp. 61-98).
Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity. Pantophlet R, Wrin T, Cavacini LA, Robinson JE, Burton DR. Virology. 2008 Nov 25;381(2):251-60. doi: 10.1016/j.virol.2008.08.032. Epub 2008 Sep 26.
An aptamer that neutralizes R5 strains of HIV-1 binds to core residues of gp120 in the CCR5 binding site. Cohen C, Forzan M, Sproat B, Pantophlet R, McGowan I, Burton D, James W. Virology. 2008 Nov 10;381(1):46-54. doi: 10.1016/j.virol.2008.08.025. Epub 2008 Sep 17.
A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120. Astronomo RD, Lee HK, Scanlan CN, Pantophlet R, Huang CY, Wilson IA, Blixt O, Dwek RA, Wong CH, Burton DR. J Virol. 2008 Jul;82(13):6359-68. doi: 10.1128/JVI.00293-08. Epub 2008 Apr 23.
Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization. Bell CH, Pantophlet R, Schiefner A, Cavacini LA, Stanfield RL, Burton DR, Wilson IA. J Mol Biol. 2008 Jan 25;375(4):969-78. Epub 2007 Nov 13.
2007
N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization. Gray ES, Moore PL, Pantophlet RA, Morris L. J Virol. 2007 Oct;81(19):10769-76. Epub 2007 Jul 18.
Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies. Quakkelaar ED, van Alphen FP, Boeser-Nunnink BD, van Nuenen AC, Pantophlet R, Schuitemaker H. J Virol. 2007 Aug;81(16):8533-42. Epub 2007 May 23.
Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis. Pantophlet R, Aguilar-Sino RO, Wrin T, Cavacini LA, Burton DR. Virology. 2007 Aug 1;364(2):441-53. Epub 2007 Apr 6.
Structure of a high-affinity “mimotope” peptide bound to HIV-1-neutralizing antibody b12 explains its inability to elicit gp120 cross-reactive antibodies. Saphire EO, Montero M, Menendez A, van Houten NE, Irving MB, Pantophlet R, Zwick MB, Parren PW, Burton DR, Scott JK, Wilson IA. J Mol Biol. 2007 Jun 8;369(3):696-709. Epub 2007 Jan 27.
Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. Dhillon AK, Donners H, Pantophlet R, Johnson WE, Decker JM, Shaw GM, Lee FH, Richman DD, Doms RW, Vanham G, Burton DR. J Virol. 2007 Jun;81(12):6548-62. Epub 2007 Apr 4.
2006
Differential roles of CD14 and toll-like receptors 4 and 2 in murine Acinetobacter pneumonia. Knapp S, Wieland CW, Florquin S, Pantophlet R, Dijkshoorn L, Tshimbalanga N, Akira S, van der Poll T. Am J Respir Crit Care Med. 2006 Jan 1;173(1):122-9. Epub 2005 Oct 6.
GP120: target for neutralizing HIV-1 antibodies. Pantophlet R, Burton DR. Annu Rev Immunol. 2006;24:739-69. Review.
2005
Comparing antigenicity and immunogenicity of engineered gp120. Selvarajah S, Puffer B, Pantophlet R, Law M, Doms RW, Burton DR. J Virol. 2005 Oct;79(19):12148-63.
2004
A dominant role for CD8+-T-lymphocyte selection in simian immunodeficiency virus sequence variation. O’Connor DH, McDermott AB, Krebs KC, Dodds EJ, Miller JE, Gonzalez EJ, Jacoby TJ, Yant L, Piontkivska H, Pantophlet R, Burton DR, Rehrauer WM, Wilson N, Hughes AL, Watkins DI. J Virol. 2004 Dec;78(24):14012-22.
Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12. Pantophlet R, Wilson IA, Burton DR. Protein Eng Des Sel. 2004 Oct;17(10):749-58. Epub 2004 Nov 12.
Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory worker. Beaumont T, Quakkelaar E, van Nuenen A, Pantophlet R, Schuitemaker H. J Virol. 2004 Jun;78(11):5651-7.
Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions. Biorn AC, Cocklin S, Madani N, Si Z, Ivanovic T, Samanen J, Van Ryk DI, Pantophlet R, Burton DR, Freire E, Sodroski J, Chaiken IM. Biochemistry. 2004 Feb 24;43(7):1928-38.
Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope. Darbha R, Phogat S, Labrijn AF, Shu Y, Gu Y, Andrykovitch M, Zhang MY, Pantophlet R, Martin L, Vita C, Burton DR, Dimitrov DS, Ji X. Biochemistry. 2004 Feb 17;43(6):1410-7.
2003
Immunofocusing: antigen engineering to promote the induction of HIV-neutralizing antibodies. Pantophlet R, Burton DR. Trends Mol Med. 2003 Nov;9(11):468-73.
Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. Pantophlet R, Wilson IA, Burton DR. J Virol. 2003 May;77(10):5889-901.
The carbohydrate epitope of the neutralizing anti-HIV-1 antibody 2G12. Scanlan CN, Pantophlet R, Wormald MR, Saphire EO, Calarese D, Stanfield R, Wilson IA, Katinger H, Dwek RA, Burton DR, Rudd PM. Adv Exp Med Biol. 2003;535:205-18. No abstract available.
Crystal structure of an intact human IgG: antibody asymmetry, flexibility, and a guide for HIV-1 vaccine design. Saphire EO, Stanfield RL, Crispin MD, Morris G, Zwick MB, Pantophlet RA, Parren PW, Rudd PM, Dwek RA, Burton DR, Wilson IA. Adv Exp Med Biol. 2003;535:55-66. Review. No abstract available.
Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. Pantophlet R, Ollmann Saphire E, Poignard P, Parren PW, Wilson IA, Burton DR. J Virol. 2003 Jan;77(1):642-58.
2002
The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1–>2 mannose residues on the outer face of gp120. Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, Wilson IA, Katinger H, Dwek RA, Rudd PM, Burton DR. J Virol. 2002 Jul;76(14):7306-21.
Identification of Acinetobacter isolates from species belonging to the Acinetobacter calcoaceticus-Acinetobacter baumannii complex with monoclonal antibodies specific for O Antigens of their lipopolysaccharides. Pantophlet R, Severin JA, Nemec A, Brade L, Dijkshoorn L, Brade H. Clin Diagn Lab Immunol. 2002 Jan;9(1):60-5.
2001
Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, Rudd PM, Dwek RA, Stanfield RL, Burton DR, Wilson IA. Science. 2001 Aug 10;293(5532):1155-9.
Generation and serological characterization of murine monoclonal antibodies against O antigens from Acinetobacter reference strains. Pantophlet R, Brade L, Brade H. Clin Diagn Lab Immunol. 2001 Jul;8(4):825-7.
O-antigen diversity among Acinetobacter baumannii strains from the Czech Republic and Northwestern Europe, as determined by lipopolysaccharide-specific monoclonal antibodies. Pantophlet R, Nemec A, Brade L, Brade H, Dijkshoorn L. J Clin Microbiol. 2001 Jul;39(7):2576-80.
Structural and serological characterisation of the O-antigenic polysaccharide of the lipopolysaccharide from Acinetobacter strain 96 (DNA group 11). Vinogradov EV, Pantophlet R, Brade H, Holst O. J Endotoxin Res. 2001;7(2):113-8.
2000
Antibody response to lipopolysaccharide in patients colonized or infected with an endemic strain of Acinetobacter genomic species 13 sensu Tjernberg and Ursing. Pantophlet R, Seifert H, Brade L, Brade H. Clin Diagn Lab Immunol. 2000 Mar;7(2):293-5.
1999
Chemical and antigenic structure of the O-polysaccharide of the lipopolysaccharides from two Acinetobacter haemolyticus strains differing only in the anomeric configuration of one glycosyl residue in their O-antigens. Pantophlet R, Haseley SR, Vinogradov EV, Brade L, Holst O, Brade H. Eur J Biochem. 1999 Jul;263(2):587-95.
Use of a murine O-antigen-specific monoclonal antibody to identify Acinetobacter strains of unnamed genomic species 13 Sensu Tjernberg and Ursing. Pantophlet R, Brade L, Brade H. J Clin Microbiol. 1999 Jun;37(6):1693-8.
Identification of Acinetobacter baumannii strains with monoclonal antibodies against the O antigens of their lipopolysaccharides. Pantophlet R, Brade L, Brade H. Clin Diagn Lab Immunol. 1999 May;6(3):323-9.
1998
Specificity of rabbit antisera against lipopolysaccharide of Acinetobacter. Pantophlet R, Brade L, Dijkshoorn L, Brade H. J Clin Microbiol. 1998 May;36(5):1245-50.
1997
Structural and serological characterisation of the O-antigenic polysaccharide of the lipopolysaccharide from Acinetobacter junii strain 65. Haseley SR, Pantophlet R, Brade L, Holst O, Brade H. Eur J Biochem. 1997 Apr 15;245(2):477-81.
Structural and serological characterisation of the O-specific polysaccharide from lipopolysaccharide of Acinetobacter calcoaceticus strain 7 (DNA group 1). Vinogradov EV, Pantophlet R, Haseley SR, Brade L, Holst O, Brade H. Eur J Biochem. 1997 Jan 15;243(1-2):167-73.
1996
Structural and serological characterisation of two O-specific polysaccharides of Acinetobacter. Vinogradov EV, Pantophlet R, Dijkshoorn L, Brade L, Holst O, Brade H. Eur J Biochem. 1996 Aug 1;239(3):602-10.
